- Email: [email protected]
New streategy of peri-operative therapy for resectable gastric cancer
Annals of Oncology 30 (Supplement 6): vi37, 2019 doi:10.1093/annonc/mdz330
SYMPOSIUM 12 : NEW STRATEGY OF PERI-OPERATIVE THERAPY FOR RESECTABLE GASTRIC CANCER 1
New streategy of peri-operative therapy for resectable gastric cancer
Salah-Eddin Al-Batran Medical Oncologist, Germany Different multimodal treatments against resectable gastric cancer has been implemented with marked regional differences. preferred strategies include postoperative chemoradiation in the US, perioperative chemotherapy in Europe, and postoperative
chemotherapy in Asian countries. Due to the lack of head to head studies comparing these strategies, there is no one world-wide accepted Standard of care, unless the fact that upfront surgery is not sufficient enough for patients of a clinical stage T2 or higher or nodal positive tumors. Recently, the new perioperative docetaxel-base combination FLOT (5-FU plus leucovorin plus oxaliplatin plus docetaxel chemotherapy) has been shown to improve all relevant outcome measures compared to perioperative ECF and emerged as the new Standard of Care for resectable gastric and gastroesophageal junction cancer.
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz330/5582870 by Heriot-Watt University user on 26 October 2019
SY12
SYMPOSIUM 12 : NEW STRATEGY OF PERI-OPERATIVE THERAPY FOR RESECTABLE GASTRIC CANCER 1
New streategy of peri-operative therapy for resectable gastric cancer
Salah-Eddin Al-Batran Medical Oncologist, Germany Different multimodal treatments against resectable gastric cancer has been implemented with marked regional differences. preferred strategies include postoperative chemoradiation in the US, perioperative chemotherapy in Europe, and postoperative
chemotherapy in Asian countries. Due to the lack of head to head studies comparing these strategies, there is no one world-wide accepted Standard of care, unless the fact that upfront surgery is not sufficient enough for patients of a clinical stage T2 or higher or nodal positive tumors. Recently, the new perioperative docetaxel-base combination FLOT (5-FU plus leucovorin plus oxaliplatin plus docetaxel chemotherapy) has been shown to improve all relevant outcome measures compared to perioperative ECF and emerged as the new Standard of Care for resectable gastric and gastroesophageal junction cancer.
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz330/5582870 by Heriot-Watt University user on 26 October 2019
SY12